India's pharmaceutical exports rose 3% to $8.04 billion in Q2 2027-28, driven by strong demand in European markets, ...
Explore groundbreaking research on biological aging, discover how cellular functions can be reprogrammed, and learn practical ...
In response to safety issues surrounding cough syrups in India, the CDSCO mandates strict monitoring of high-risk solvents ...
Eli Lilly, known for its blockbuster weight-loss and anti-diabetes drugs, is now focusing on neurosciences, with significant ...
Piramal Pharma reduces reliance on Chinese raw materials to single-digit levels to enhance supply-chain resilience amid ...
Discover how India is addressing cancer drug affordability with a new pricing strategy that aims to lower costs for patients ...
Despite beating quarterly sales and profit expectations, GSK's stock fell due to concerns over its drug pipeline and weak ...
Eli Lilly has announced that its experimental obesity drug, retatrutide, has outperformed Novo's Ozempic in a Phase 3 trial, ...
The Indian Patent Office has rejected a patent application for the BPaL regimen, a groundbreaking treatment for ...
Mumbai: In a major cost-cutting move, Sun Pharma Advanced Research Company Ltd. (SPARC) has decided to downsize its total workforce “by 40 per cent”, with its US operations facing the largest impact, ...
Sandoz, the Swiss generic drugmaker, adjusts its sales growth forecast to 5-6% due to supply constraints, impacting investor confidence and leading to an 8% drop in shares. The company highlights ...
Mumbai: Bengaluru-based Biocon has secured license to launch its proposed biosimilar of Johnson and Johnson’s blockbuster therapy, Stelara in nine more markets. The latest agreement singed with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results